[go: up one dir, main page]

JPH04266864A - Production of l-dopa - Google Patents

Production of l-dopa

Info

Publication number
JPH04266864A
JPH04266864A JP4781591A JP4781591A JPH04266864A JP H04266864 A JPH04266864 A JP H04266864A JP 4781591 A JP4781591 A JP 4781591A JP 4781591 A JP4781591 A JP 4781591A JP H04266864 A JPH04266864 A JP H04266864A
Authority
JP
Japan
Prior art keywords
dopa
supersaturated solution
racemization
fatty acid
crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4781591A
Other languages
Japanese (ja)
Inventor
Hirokazu Hasegawa
弘和 長谷川
Masakuni Matsuoka
松岡 正▲くに▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP4781591A priority Critical patent/JPH04266864A/en
Publication of JPH04266864A publication Critical patent/JPH04266864A/en
Pending legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PURPOSE:To obtain L-dopa useful for the therapy of Parkinson's disease by preferential crystallization, with racemization, from DLdopa. CONSTITUTION:L-dopa crystal is inoculated in a supersaturated solution of DL-dopa containing an aromatic aldehyde plus lower fatty acid at the molar ratio >=0.3 based on the DL-dopa to effect crystallization of L-dopa from said solution under the racemization condition for the dissolved D-dopa. With the present method, the desired L-dopa can be obtained in a single step without the need for any troublesome treatments from DL-dopa; therefore, being highly useful from the viewpoint of industry.

Description

【発明の詳細な説明】[Detailed description of the invention]

【0001】0001

【産業上の利用分野】本発明はパーキンソン病の治療に
有用なL−ドーパをDL−ドーパからラセミ化を伴う優
先晶析法により製造する方法に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for producing L-dopa useful for the treatment of Parkinson's disease from DL-dopa by preferential crystallization accompanied by racemization.

【0002】0002

【従来の技術】一般に合成法により得られるドーパ、即
ち、[3−(3,4−ジヒドロキシフェニル)アラニン
]はDL−体であるため、L−体を得るためには更に光
学分割することが必要である。DL−ドーパの光学分割
としては優先晶析による種々の方法が報告されている。 例えば45℃におけるDL−ドーパの0.3N塩酸飽和
溶液を32℃に冷却してL−ドーパの種晶を接種する方
法(米国特許第3,405,159号明細書)、50〜
100℃におけるDL−ドーパの飽和水溶液を45〜9
5℃に冷却してL−ドーパの種晶を接種する方法(特開
昭47−34246号公報)、30℃以下のDL−ドー
パの水性過飽和溶液にL−ドーパの針状晶を接種する方
法(特公昭49−31974号公報)、30℃よりも高
い温度のDL−ドーパ−の水性過飽和溶液にL−ドーパ
の正方晶の存在下、L−ドーパの針状晶を接種する方法
(特公昭49−31975号公報)、DL−ドーパ・1
/2塩酸塩の過飽和溶液にL−ドーパ・1/2塩酸塩結
晶を接種する方法(特公昭50−7073号公報)、D
L−ドーパおよびD−ドーパ・1/2塩酸塩を含む水性
過飽和溶液にL−ドーパおよび/またはL−ドーパ・1
/2塩酸塩の結晶を接種する方法(特公昭50−124
18号公報、同50−12419号公報)、DL−ドー
パと少量のL−ドーパを含む水性過飽和溶液を冷却して
L−ドーパを晶析する方法(特公昭51−36260号
公報、同51−36261号公報)などが知られている
[Prior Art] Dopa, that is, [3-(3,4-dihydroxyphenyl)alanine], which is generally obtained by a synthetic method, is in the DL-form, so it must be further optically resolved to obtain the L-form. is necessary. Various methods using preferential crystallization have been reported for optical resolution of DL-DOPA. For example, a method in which a 0.3N hydrochloric acid saturated solution of DL-dopa at 45°C is cooled to 32°C and seed crystals of L-dopa are inoculated (U.S. Pat. No. 3,405,159), 50-
A saturated aqueous solution of DL-DOPA at 100°C was heated to 45-9
A method of inoculating seed crystals of L-dopa after cooling to 5°C (Japanese Patent Application Laid-Open No. 47-34246), a method of inoculating needle-like crystals of L-dopa into an aqueous supersaturated solution of DL-dopa at 30°C or lower (Japanese Patent Publication No. 49-31974), a method of inoculating an aqueous supersaturated solution of DL-dopa at a temperature higher than 30°C with needle-like crystals of L-dopa in the presence of tetragonal crystals of L-dopa (Japanese Patent Publication No. 49-31974); 49-31975), DL-Dopa-1
Method of inoculating L-dopa 1/2 hydrochloride crystals into a supersaturated solution of /2 hydrochloride (Japanese Patent Publication No. 7073/1983), D
Add L-dopa and/or L-dopa 1 to an aqueous supersaturated solution containing L-dopa and D-dopa 1/2 hydrochloride.
/2 Method of inoculating hydrochloride crystals (Special Publication No. 50-124)
No. 18, No. 50-12419), a method of crystallizing L-dopa by cooling an aqueous supersaturated solution containing DL-dopa and a small amount of L-dopa (Japanese Patent Publication No. 51-36260, No. 51-124) 36261) and the like are known.

【0003】0003

【発明が解決しようとする問題点】しかしながらこれら
の優先晶析法は工業的に有利な方法であるが、なお技術
的に制約を有する。優先晶析法は、D−ドーパが過飽和
状態で存在する中でL−ドーパのみを晶析させるのであ
るから、晶析結晶の分離、取得はD−ドーパの自然起晶
が生じない状態で行なわなければならない。一方、光学
活性アミノ酸のラセミ化は種々の方法が報告されており
、その一つに光学活性アミノ酸を低級脂肪酸および脂肪
族または芳香族アルデヒドの共存下にラセミ化する方法
(特開昭57−123150号公報)があるが、L−ド
ーパを優先晶析する際にDL−ドーパの過飽和溶液から
溶存するD−ドーパのラセミ化反応を伴うL−ドーパの
製法は知られていない。
[Problems to be Solved by the Invention] However, although these preferential crystallization methods are industrially advantageous, they still have technical limitations. Since the preferential crystallization method crystallizes only L-dopa in the presence of supersaturated D-dopa, separation and acquisition of crystallized crystals must be carried out in a state where spontaneous crystallization of D-dopa does not occur. There must be. On the other hand, various methods have been reported for racemizing optically active amino acids, one of which is a method of racemizing optically active amino acids in the coexistence of lower fatty acids and aliphatic or aromatic aldehydes (Japanese Patent Application Laid-Open No. 123150/1989). However, there is no known method for producing L-dopa that involves a racemization reaction of D-dopa dissolved from a supersaturated solution of DL-dopa during preferential crystallization of L-dopa.

【0004】本発明者らはこの点について鋭意検討した
結果、低級脂肪酸が共存するDL−ドーパの過飽和溶液
にDL−ドーパに対し、0.3モル比以上の芳香族アル
デヒドを添加し、ついでL−ドーパの結晶を接種すると
、該過飽和溶液からL−ドーパが優先晶析するとともに
これと並行して該過飽和溶液中に溶存するD−ドーパは
容易にラセミ化されること、結晶状態にあるL−ドーパ
は溶存するD−ドーパのラセミ化条件下でもラセミ化さ
れず安定であること、従って該D−ドーパのラセミ化条
件下にL−ドーパの優先晶析と並行してラセミ化反応が
進行するため、優先晶析中の溶液は常にL−ドーパとD
−ドーパのほぼ同量存在する溶液として得られ、その結
果、過飽和にあったDL−ドーパはすべてL−ドーパと
して取得することができることを見出し本発明を完成し
た。
As a result of intensive studies on this point, the present inventors added aromatic aldehyde at a molar ratio of 0.3 or more to DL-dopa to a supersaturated solution of DL-dopa in which lower fatty acids coexist, and then - When dopa crystals are inoculated, L-dopa preferentially crystallizes from the supersaturated solution, and in parallel, D-dopa dissolved in the supersaturated solution is easily racemized; - Dopa is stable without being racemized even under the racemization conditions of dissolved D-dopa; therefore, under the racemization conditions of D-dopa, the racemization reaction proceeds in parallel with the preferential crystallization of L-dopa. Therefore, the solution during preferential crystallization always contains L-dopa and D
The present invention has been completed by discovering that DL-dopa can be obtained as a solution containing approximately the same amount of -dopa, and as a result, all of the supersaturated DL-dopa can be obtained as L-dopa.

【0005】[0005]

【問題点を解決しようとする手段】本発明はDL−ドー
パの過飽和溶液よりL−ドーパを優先晶析する際に、D
L−ドーパに対し0.3モル比以上の芳香族アルデヒド
、および低級脂肪酸の存在下、該過飽和溶液にL−ドー
パの結晶を添加し、溶存するD−ドーパのラセミ化条件
下に該過飽和溶液からL−ドーパを優先晶析させること
を特徴とするL−ドーパの製造法である。
[Means for Solving the Problems] The present invention provides for the preferential crystallization of L-dopa from a supersaturated solution of DL-dopa.
In the presence of an aromatic aldehyde and a lower fatty acid in a molar ratio of 0.3 or more to L-dopa, crystals of L-dopa are added to the supersaturated solution, and the supersaturated solution is heated under racemization conditions for the dissolved D-dopa. This is a method for producing L-dopa, which is characterized by preferentially crystallizing L-dopa from.

【0006】本発明に用いる低級脂肪酸は炭素数1〜3
の飽和脂肪酸であり、具体的にはギ酸、酢酸、プロピオ
ン酸であり、とりわけ酢酸が好ましい。低級脂肪酸の濃
度は限定されないが、通常は10v/v%以上、好まし
くは30v/v%以上である。
[0006] The lower fatty acids used in the present invention have 1 to 3 carbon atoms.
saturated fatty acids, specifically formic acid, acetic acid, and propionic acid, with acetic acid being particularly preferred. The concentration of lower fatty acids is not limited, but is usually 10 v/v% or more, preferably 30 v/v% or more.

【0007】本発明で使用する芳香族アルデヒドはベン
ズアルデヒド、サリチルアルデヒド、m−ヒドロキシベ
ンズアルデヒド、およびp−ヒドロキシベンズアルデヒ
ドの様な水酸基を有するかまたは有しないベンズアルデ
ヒドである。これらのアルデヒドの使用量は、原料DL
−ドーパに対し0.3モル比以上である。
The aromatic aldehydes used in the present invention are benzaldehydes with or without hydroxyl groups, such as benzaldehyde, salicylaldehyde, m-hydroxybenzaldehyde, and p-hydroxybenzaldehyde. The amount of these aldehydes used is based on the raw material DL
- a molar ratio of 0.3 or more to dopa;

【0008】本発明における優先晶析およびラセミ化を
並行して行なう操作は水性溶媒中でも、あるいは無水溶
媒中でも行なうことができる。この操作は先ず溶媒、D
L−ドーパ、低級脂肪酸および芳香族アルデヒドを任意
の順序で混合し、加熱し、ついで冷却あるいは濃縮して
得られるDL−ドーパの過飽和溶液にL−ドーパの種晶
を接種し、撹拌することによりL−ドーパが晶析すると
ともに、D−ドーパのラセミ化が好適に進行する。当該
操作は室温から過飽和溶液の還流温度の範囲で実施でき
るが、一般的には50〜100℃で行なうことが好まし
い。
[0008] In the present invention, the preferential crystallization and racemization can be carried out in parallel in an aqueous solvent or an anhydrous solvent. This operation begins with the solvent, D
By inoculating seed crystals of L-dopa into a supersaturated solution of DL-dopa obtained by mixing L-dopa, lower fatty acids, and aromatic aldehydes in any order, heating, and then cooling or concentrating, and stirring. While L-dopa crystallizes, racemization of D-dopa progresses suitably. This operation can be carried out at a temperature ranging from room temperature to the reflux temperature of the supersaturated solution, but is generally preferably carried out at 50 to 100°C.

【0009】かくすることにより、過飽和分のDL−ド
ーパを実質上すべてL−ドーパに変換して取得すること
ができる。本発明においては、DL−ドーパの過飽和分
が変換反応の対象となることから、更に効果的に実施す
るためには引き続きDL−ドーパの過飽和分を添加すれ
ばよい。
[0009] By doing so, substantially all of the supersaturated DL-dopa can be converted into L-dopa. In the present invention, since the supersaturated portion of DL-dopa is the target of the conversion reaction, in order to carry out the reaction more effectively, the supersaturated portion of DL-dopa may be added subsequently.

【0010】かくして得られるL−ドーパは濾過、遠心
分離など公知に方法により採取することができる。
[0010] The L-dopa thus obtained can be collected by known methods such as filtration and centrifugation.

【0011】[0011]

【実施例】以下に本発明の実施例を示すが、本発明はこ
れによって限定されるものではない。 [実施例1]DL−ドーパ  22.2gを85℃の3
3%酢酸水溶液360mlに溶解し、サリチルアルデヒ
ド4mlを加え、過剰結晶を除去後92℃に昇温した。 ついで、溶液を75℃に保ち、L−ドーパ2.2gを接
種し、3時間後に70℃、4.5時間後に65℃まで温
度を下げて6時間後まで撹拌した。析出した結晶を濾取
し、少量のエタノールで洗浄、乾燥して光学純度100
%のL−ドーパ3.4g(接種した量を除く。以下の実
施例でも同じ)を得た。
[Examples] Examples of the present invention are shown below, but the present invention is not limited thereto. [Example 1] 22.2 g of DL-dopa was heated at 85° C.
It was dissolved in 360 ml of a 3% aqueous acetic acid solution, 4 ml of salicylaldehyde was added, and after removing excess crystals, the temperature was raised to 92°C. Next, the solution was maintained at 75°C, and 2.2 g of L-dopa was inoculated, and the temperature was lowered to 70°C after 3 hours, to 65°C after 4.5 hours, and stirred until 6 hours later. The precipitated crystals are collected by filtration, washed with a small amount of ethanol, and dried to an optical purity of 100.
% L-dopa (excluding the inoculated amount; the same applies to the following examples) was obtained.

【0012】[実施例2]DL−ドーパ18.7gを8
5℃の50%酢酸水溶液360mlに溶解し、サリチル
アルデヒド3.6mlを加えて92℃に昇温した。つい
で、溶液を90℃に保ち、L−ドーパ2.0gを接種し
、30分後に70℃、2時間後に50℃まで温度を下げ
て4時間後まで撹拌した。析出した結晶を瀘取し、少量
のエタノールで洗浄、乾燥して光学純度97.7%のL
−ドーパ2.1gを得た。
[Example 2] 18.7 g of DL-Dopa was added to 8
It was dissolved in 360 ml of 50% acetic acid aqueous solution at 5°C, 3.6 ml of salicylaldehyde was added, and the temperature was raised to 92°C. Next, the solution was maintained at 90°C, 2.0 g of L-dopa was inoculated, and the temperature was lowered to 70°C after 30 minutes, to 50°C after 2 hours, and stirred until 4 hours later. The precipitated crystals were filtered, washed with a small amount of ethanol, and dried to obtain L with an optical purity of 97.7%.
- Obtained 2.1 g of Dopa.

【0013】[実施例3]DL−ドーパ15.4gとサ
リチルアルデヒド18mlを85℃の33%水溶液に溶
解し、92℃に昇温した。ついで、温度を70℃まで下
げてL−ドーパ2.0gを接種し、1.5時間撹拌して
、3時間後50℃まで温度を下げた。析出した結晶を濾
取し、少量のエタノールで洗浄、乾燥して光学純度98
.4%のL−ドーパ4.6gを得た。
[Example 3] 15.4 g of DL-dopa and 18 ml of salicylaldehyde were dissolved in a 33% aqueous solution at 85°C, and the temperature was raised to 92°C. Then, the temperature was lowered to 70°C, 2.0 g of L-dopa was inoculated, stirred for 1.5 hours, and after 3 hours the temperature was lowered to 50°C. The precipitated crystals were collected by filtration, washed with a small amount of ethanol, and dried to an optical purity of 98.
.. 4.6 g of 4% L-dopa was obtained.

【0014】[0014]

【発明の効果】本発明によれば、DL−ドーパから、何
ら複雑な処理を要せず1工程で所望のL−ドーパを高収
率で得ることが出来る点で産業上極めて有用性の高いも
のである。
[Effects of the Invention] According to the present invention, the desired L-dopa can be obtained in high yield from DL-dopa in one step without requiring any complicated treatment, which is extremely useful industrially. It is something.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】DL−ドーパの過飽和溶液よりL−ドーパ
を優先晶析する際に、DL−ドーパに対し0.3モル比
以上の芳香族アルデヒド、および低級脂肪酸の共存下、
該過飽和溶液にL−ドーパの結晶を添加し、溶存するD
−ドーパのラセミ化条件下に該過飽和溶液からL−ドー
パを優先晶析させることを特徴とするL−ドーパの製造
法。
Claim 1: When preferentially crystallizing L-dopa from a supersaturated solution of DL-dopa, in the coexistence of an aromatic aldehyde and a lower fatty acid in a molar ratio of 0.3 or more to DL-dopa,
L-dopa crystals are added to the supersaturated solution, and the dissolved D
- A method for producing L-dopa, which comprises preferentially crystallizing L-dopa from the supersaturated solution under dopa racemization conditions.
【請求項2】低級脂肪酸が炭素数1〜3の飽和脂肪酸で
あり、芳香族アルデヒドが水酸基を有するか、あるいは
有しないベンズアルデヒドである請求項1記載の製造法
2. The method according to claim 1, wherein the lower fatty acid is a saturated fatty acid having 1 to 3 carbon atoms, and the aromatic aldehyde is benzaldehyde with or without a hydroxyl group.
【請求項3】低級脂肪酸が酢酸であり、芳香族アルデヒ
ドがサリチルアルデヒドである請求項1記載の製造法。
3. The method according to claim 1, wherein the lower fatty acid is acetic acid and the aromatic aldehyde is salicylaldehyde.
JP4781591A 1991-02-20 1991-02-20 Production of l-dopa Pending JPH04266864A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4781591A JPH04266864A (en) 1991-02-20 1991-02-20 Production of l-dopa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4781591A JPH04266864A (en) 1991-02-20 1991-02-20 Production of l-dopa

Publications (1)

Publication Number Publication Date
JPH04266864A true JPH04266864A (en) 1992-09-22

Family

ID=12785858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4781591A Pending JPH04266864A (en) 1991-02-20 1991-02-20 Production of l-dopa

Country Status (1)

Country Link
JP (1) JPH04266864A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010001235A (en) * 2008-06-19 2010-01-07 Sumitomo Chemical Co Ltd Method for producing optically active 4-amino-3-substituted phenylbutanoic acid
JP2012082223A (en) * 2004-02-27 2012-04-26 Ajinomoto Co Inc Method for producing monatin

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012082223A (en) * 2004-02-27 2012-04-26 Ajinomoto Co Inc Method for producing monatin
JP5319885B2 (en) * 2004-02-27 2013-10-16 味の素株式会社 Monatin manufacturing method
JP2010001235A (en) * 2008-06-19 2010-01-07 Sumitomo Chemical Co Ltd Method for producing optically active 4-amino-3-substituted phenylbutanoic acid
US8791295B2 (en) 2008-06-19 2014-07-29 Sumitomo Chemical Company, Limited Method of producing purified optically acitve 4-amino-3-(substituted phenyl)butanoic acid compound

Similar Documents

Publication Publication Date Title
CA2557274C (en) Method for producing monatin
JP2607131B2 (en) Optical resolution method of 2- (6-methoxy-2-naphthyl) propionic acid
JPH02138237A (en) Process for producing enantiomeric 2-arylpropionic acid
JPH02231457A (en) Method for synthesizing L-(-)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
EP0075318A2 (en) p-Hydroxyphenylglycine alpha-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPH0570415A (en) Process for resolving optically active isomer mixture of alpha-amino acids
JPH04266864A (en) Production of l-dopa
JPS6340180B2 (en)
EP0044984B1 (en) Process for the optical resolution of mixtures of d- and l-2-(6-methoxy-2-naphthyl)-propionic acids, the cinchonidine salt of d-2-(6-methoxy-2-naphthyl)-propionic acid and the preparation thereof
JP2000509068A (en) Process for preparing enantiomerically pure azetidine-2-carboxylic acid
US4434107A (en) Process for preparing an optically active p-hydroxyphenylglycine or a salt thereof
JP2004511476A (en) Method for producing R (+) α-lipoic acid
JPH11228512A (en) Method for producing D-alloisoleucine and intermediate for production
JPH0134979B2 (en)
JPS6360955A (en) Manufacture of l-dopa
PT1981840E (en) Process for manufacturing entacapone
JP3312451B2 (en) Method for producing optically active trans-1,2-diaminocyclohexane
JPH01131143A (en) Optical resolution of d,l-carnitinenitrile chloride
JPH035382B2 (en)
JPH06340599A (en) Production of optically active 2-aminolactic acid
JPS6363646A (en) Production of optically active homophenylalanine
JP2856331B2 (en) Method for producing 2,2-diamino-1,1-binaphthyl
JP2505487B2 (en) Racemization of optically active lysine
JPH0798802B2 (en) Process for producing optically active indoline-2-carboxylic acid
JP2574254B2 (en) Optical resolution method